Erin M Kelly1, Jennifer L Dodge2, Monika Sarkar2, Audrey L French3, Phyllis C Tien4, Marshall J Glesby5, Elizabeth T Golub6, Michael Augenbraun7, Michael Plankey8, Marion G Peters2. 1. Department of Medicine, University of California, San Francisco Department of Medicine, University of Ottawa, Ontario, Canada. 2. Department of Medicine, University of California, San Francisco. 3. Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois. 4. Department of Medicine, University of California, San Francisco Department of Veterans Affairs Medical Center, San Francisco, California. 5. Infectious Diseases, Weill Cornell Medical College, New York, New York. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 7. Infectious Diseases, State University of New York, Downstate Medical Center, Brooklyn; 8. Department of Medicine, Georgetown University Medical Center, Washington D.C.
Abstract
BACKGROUND: Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated with liver fibrosis progression in retrospective analyses of patients with chronic hepatitis C (HCV). We studied long-term effects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV enrolled in the Women's Interagency HIV Study (WIHS). METHODS: Liver fibrosis was categorized according to FIB-4 scores as none, moderate, or significant. THC and alcohol use were quantified as average exposure per week. Associations between THC use and progression to significant fibrosis were assessed using Cox proportional hazards regression. RESULTS: Among 575 HIV/HCV-coinfected women followed for a median of 11 (interquartile range, 6-17) years, 324 (56%) reported no THC use, 141 (25%) less than weekly use, 70 (12%) weekly use, and 40 (7%) daily use at WIHS entry. In univariable analysis, entry FIB-4 score (hazard ratio [HR], 2.26 [95% confidence interval {CI}, 1.88-2.73], P < .001), log HCV RNA (HR, 1.19 [95% CI, 1.02-1.38], P = .02), tobacco use (HR, 1.37 [95% CI, 1.02-1.85], P = .04), CD4(+) count (risk per 100-cell increase: HR, 0.90 [95% CI, .86-.95], P < .001), and log HIV RNA (HR, 1.18 [95% CI, 1.05-1.32], P = .005) were associated with progression to significant fibrosis, as was cumulative alcohol use in follow-up (HR, 1.03 [95% CI, 1.02-1.04], P < .001). In multivariable analysis, entry FIB-4, entry CD4(+) count, and cumulative alcohol use remained significant. Cumulative THC use was not associated with fibrosis progression (HR, 1.01 [95% CI, .92-1.10], P = .83). CONCLUSIONS: In this large cohort of HIV/HCV-coinfected women, THC was not associated with progression to significant liver fibrosis. Alcohol use was independently associated with liver fibrosis, and may better predict fibrosis progression in HIV/HCV-coinfected women.
BACKGROUND:Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated with liver fibrosis progression in retrospective analyses of patients with chronic hepatitis C (HCV). We studied long-term effects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV enrolled in the Women's Interagency HIV Study (WIHS). METHODS:Liver fibrosis was categorized according to FIB-4 scores as none, moderate, or significant. THC and alcohol use were quantified as average exposure per week. Associations between THC use and progression to significant fibrosis were assessed using Cox proportional hazards regression. RESULTS: Among 575 HIV/HCV-coinfectedwomen followed for a median of 11 (interquartile range, 6-17) years, 324 (56%) reported no THC use, 141 (25%) less than weekly use, 70 (12%) weekly use, and 40 (7%) daily use at WIHS entry. In univariable analysis, entry FIB-4 score (hazard ratio [HR], 2.26 [95% confidence interval {CI}, 1.88-2.73], P < .001), log HCV RNA (HR, 1.19 [95% CI, 1.02-1.38], P = .02), tobacco use (HR, 1.37 [95% CI, 1.02-1.85], P = .04), CD4(+) count (risk per 100-cell increase: HR, 0.90 [95% CI, .86-.95], P < .001), and log HIV RNA (HR, 1.18 [95% CI, 1.05-1.32], P = .005) were associated with progression to significant fibrosis, as was cumulative alcohol use in follow-up (HR, 1.03 [95% CI, 1.02-1.04], P < .001). In multivariable analysis, entry FIB-4, entry CD4(+) count, and cumulative alcohol use remained significant. Cumulative THC use was not associated with fibrosis progression (HR, 1.01 [95% CI, .92-1.10], P = .83). CONCLUSIONS: In this large cohort of HIV/HCV-coinfectedwomen, THC was not associated with progression to significant liver fibrosis. Alcohol use was independently associated with liver fibrosis, and may better predict fibrosis progression in HIV/HCV-coinfectedwomen.
Authors: S Bátkai; Z Járai; J A Wagner; S K Goparaju; K Varga; J Liu; L Wang; F Mirshahi; A D Khanolkar; A Makriyannis; R Urbaschek; N Garcia; A J Sanyal; G Kunos Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: Eleonora Patsenker; Matthias Stoll; Gunda Millonig; Abbas Agaimy; Till Wissniowski; Vreni Schneider; Sebastian Mueller; Rudolf Brenneisen; Helmut K Seitz; Matthias Ocker; Felix Stickel Journal: Mol Med Date: 2011-08-19 Impact factor: 6.354
Authors: David van der Poorten; Mahsa Shahidi; Enoch Tay; Jayshree Sesha; Kayla Tran; Duncan McLeod; Jane S Milliken; Vikki Ho; Lionel W Hebbard; Mark W Douglas; Jacob George Journal: PLoS One Date: 2010-09-17 Impact factor: 3.240
Authors: Javier Muñoz-Luque; Josefa Ros; Guillermo Fernández-Varo; Sònia Tugues; Manuel Morales-Ruiz; Carlos E Alvarez; Scott L Friedman; Vicente Arroyo; Wladimiro Jiménez Journal: J Pharmacol Exp Ther Date: 2007-11-20 Impact factor: 4.030
Authors: Maurizio Baldassarre; Ferdinando A Giannone; Lucia Napoli; Alessandra Tovoli; Carmen S Ricci; Manuel Tufoni; Paolo Caraceni Journal: Liver Int Date: 2013-07-25 Impact factor: 5.828
Authors: Monika Sarkar; Peter Bacchetti; Phyllis Tien; Elizabeth Mileti; Audrey L French; Brian R Edlin; Marla Keller; Eric Seaberg; Marek J Nowicki; Mary Young; Marion G Peters Journal: Dig Dis Sci Date: 2012-11-24 Impact factor: 3.199
Authors: Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet Journal: Curr HIV Res Date: 2021 Impact factor: 1.341